Douglas C. Lane & Associates’s Express Scripts Holding Company ESRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2015
Q4
$833K Sell
9,534
-1,431
-13% -$123K 0.02% 159
2015
Q3
$888K Sell
10,965
-962
-8% -$83.8K 0.03% 155
2015
Q2
$1.06M Sell
11,927
-492
-4% -$43K 0.03% 148
2015
Q1
$1.08M Buy
12,419
+2,976
+32% +$250K 0.03% 144
2014
Q4
$800K Buy
9,443
+1,259
+15% +$98.4K 0.02% 154
2014
Q3
$578K Buy
8,184
+120
+1% +$8.55K 0.02% 158
2014
Q2
$559K Buy
8,064
+744
+10% +$52.4K 0.02% 158
2014
Q1
$550K Buy
7,320
+1,275
+21% +$95.5K 0.02% 154
2013
Q4
$425K Buy
6,045
+446
+8% +$29.1K 0.01% 159
2013
Q3
$346K Buy
5,599
+526
+10% +$34K 0.01% 165
2013
Q2
$313K Buy
+5,073
New +$305K 0.01% 170

Other funds holding ESRX

Douglas C. Lane & Associates's ESRX Position: Q4 2015 in Review

Douglas C. Lane & Associates reduced its Express Scripts Holding Company (ESRX) stake by 13% in Q4 2015, selling an estimated $123K and leaving 9,534 shares worth $833K. The position accounts for 0.02% of the portfolio, ranked #159.

Douglas C. Lane & Associates first reported a position in ESRX in Q2 2013 and has held it in 11 quarters since. The position peaked at $1.08M in Q1 2015. 1,295 funds tracked by Wall St. Rank hold ESRX as of Q4 2015.

  • Douglas C. Lane & Associates held 9,534 shares of Express Scripts Holding Company worth $833K as of Q4 2015.
  • Douglas C. Lane & Associates sold 1,431 Express Scripts Holding Company shares in Q4 2015, an estimated $123K.
  • Express Scripts Holding Company made up 0.02% of Douglas C. Lane & Associates's portfolio in Q4 2015, its #159 holding.
  • Douglas C. Lane & Associates first reported a position in Express Scripts Holding Company in Q2 2013 and has held it in 11 quarters since.
  • Douglas C. Lane & Associates's Express Scripts Holding Company position peaked at $1.08M in Q1 2015.
  • 1,295 funds tracked by Wall St. Rank held Express Scripts Holding Company as of Q4 2015.

Based on Douglas C. Lane & Associates's 13F filing for Q4 2015, filed 25 Jan 2016.